STAAR Surgical Celebrates Over 350,000 Successful Visian® ICL™ Implants at ASCRS Symposium in San Francisco

  STAAR Surgical Celebrates Over 350,000 Successful Visian® ICL™ Implants at
                       ASCRS Symposium in San Francisco

~Reviews by Key Surgeons of New CentraFLOW™ Technology and V5 ICL with
Preloaded Delivery System

~~Investor Briefing Presentations to be Webcast Live

PR Newswire

MONROVIA, Calif., April 17, 2013

MONROVIA, Calif., April 17, 2013 /PRNewswire/ -- STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally
invasive ophthalmic products, today announced its significant participation in
the upcoming annual Symposium of the American Society for Cataract and
Refractive Surgery (ASCRS) to be held in San Francisco from April 19 through

The Company will be highlighting the Visian® ICL™ product line, the fastest
growing refractive technology in the world, with patient implants now
exceeding 350,000. Nearly 100,000 of STAAR's Visian Toric ICL lenses have
been successfully implanted in patients throughout the 60 markets where it is
approved. The Company's CentraFLOW™, which simplifies ICL treatment by making
it a one-step process, has been implanted in over 16,000 patient procedures.
STAAR's CentraFLOW technology which utilizes the KS-AquaPORT™ makes the ICL
implant procedure more convenient and cost effective for both the patient and

STAAR Surgical will also be highlighting a number of its innovative IOL
developments and delivery system technologies, specifically its new family of
Toric IOLs and its new Preloaded Acrylic IOLs in the KS-SP and KS-SX product

"We continue to be encouraged by increasing market share gains of our Visian
ICL worldwide while there is growing evidence of continued decline in LASIK
procedures," said Barry G. Caldwell, president and CEO of STAAR Surgical.
"With the introduction over the past few years of several truly innovative ICL
enhancements, improved visual results, and comfort for the patient and a
simpler, more efficient procedure for the surgeon, we have seen increased
refractive surgeon interest in our solutions, especially as an alternative to
LASIK surgery. Our participation at the conference will feature several
clinical presentations by leading ophthalmologists from throughout the world
on ICL and IOL technology, relative to their experience with our Visian ICL
products, as well as our premium IOLs, including the nanoFLEX Toric IOL for
the European markets. In addition, we will have again expanded the STAAR
Surgical booth in order to satisfy the growing interest in our technologies."

During a breakfast meeting for professional investors and analysts on
Saturday, April 20, presentations will feature Dr. Erik Mertens, Medical
Director and founder of the Medipolis Eye Centre in Antwerp, Belgium, who will
discuss the results and benefits his patients have received with the Visian
ICL CentraFLOW technology. He will also present his recent experience with a
custom implant having an enhanced optic design similar to that of the
Company's next generation ICL, the V5. The patient receiving that custom
implant will be on hand to offer his personal testimony on the new optics.
Dr. Mertens will also review the preloaded feature on the V5 ICL and how this
may impact his procedure time when it becomes available later this year. In
addition, an update will be provided on patient experience with the new
nanoFLEX Toric IOL in Italy and the Dominican Republic, as well as the overall
progress of commercialization of the nanoFLEX Toric in Europe.

Mr. Caldwell will provide a brief update on the Company's operations through
the first quarter. Preliminary results announced on April 9, 2013 included
revenues of $18 million, representing approximately 16% year over year growth
and Visian ICL revenue growth of approximately 24%, which exceeded the $10
million level in quarterly revenue for the first time in the Company's

A live audio webcast of the presentation will be available at 7:30 a.m.
PT/10:30 a.m. ET from the investor section of the Company's website at

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25
years, designs, develops, manufactures and markets implantable lenses for the
eye and delivery systems therefor. All of these lenses are foldable, which
permits the surgeon to insert them through a small incision. STAAR's lens used
in refractive surgery as an alternative to LASIK is called an Implantable
Collamer® Lens or "ICL." A lens used to replace the natural lens after
cataract surgery is called an intraocular lens or "IOL." Over 350,000 Visian
ICLs have been implanted to date; to learn more about the ICL go to: STAAR has approximately 300 full time employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, it
manufactures in the following locations: Nidau, Switzerland; Ichikawa City,
Japan; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit
the Company's website at

Safe Harbor

All statements in this press release that are not statements of historical
fact are forward-looking statements, including any estimates of future
revenues or revenue growth, any statements about the effect of new product
approvals on our business, statements about planned product launches, any
statements of belief and any statements of assumptions underlying any of the

These statements are based on expectations and assumptions as of the date of
this press release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those described in the
forward-looking statements. The risks and uncertainties include the following:
the effect of poor global economic conditions on sales, especially sales of
products like the ICL used in non-reimbursed elective procedures; our limited
resources to promote new products; the risk that product launches may be
affected by unplanned delays or be less successful than we expect; the risk
that greater than expected demand for new products can result in backlog, the
willingness of surgeons and patients to adopt a new product and procedure; the
entrenched market position of laser-based procedures for many conditions
treated by the Visian ICL; and patterns of Visian ICL use that have typically
limited our penetration of the refractive surgery market. STAAR assumes no
obligation to update its forward-looking statements to reflect future events
or actual outcomes and does not intend to do so.

CONTACT: Investors                    Media
          EVC Group                   EVC Group
          Douglas Sherk, 415-652-9100 Amy Phillips, 412-327-9499
          Leigh Salvo, 415-568-9348

SOURCE STAAR Surgical Company

Press spacebar to pause and continue. Press esc to stop.